Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma

Background: We aimed to investigate whether there were any diffusion tensor imaging (DTI) value differences in brain metastases (BM) due to lung adenocarcinoma based on the epidermal growth factor receptor (EGFR) gene mutation status. Material and Methods: 17 patients with 32 solid intracranial metastatic lesions from lung adenocarcinoma were included prospectively. Patients were divided according to the EGFR mutation status as EGFR (+) (group 1, n:8) and EGFR wild type (group 2, n:9). The fractional anisotropy (FA), apparent diffusion coefficient (ADC), normalized ADC (nADC), axial diffusivity (AD), and radial diffusivity (RD) values were measured from the solid component of the metastatic lesions and nADC values were calculated. DTI values were compared between group 1 and group 2. Receiver-operating characteristic analysis was used to obtain cut-off values for the parameters presenting a statistical difference between the EGFR gene mutation positive and wild type group. Results: There were statistically significant differences in measured ADC, nADC, AD, and RD values between group 1 and group 2. The ADC, nADC, AD, and RD values were significantly lower in group 1. There was no significant difference in FA values between two groups. Analysis by the ROC curve method revealed a cut-off value of ≤721 x 10-6 mm2/s for ADC (Sensitivity=72.7, Specificity=85.7); ≤0.820 for nADC (Sensitivity=72.7, Specificity=90.5), ≤886 for AD (Sensitivity=81.8, Specificity=81.0), and ≤588 for RD (Sensitivity=63.6, Specificity=90.5) in differentiating EGFR mutation (+) group from wild type group. Conclusion: Combination of the decreased ADC, nADC, AD, and RD values in BM due to lung adenocarcinoma can be important for predicting the EGFR gene mutation status. DTI features of the brain metastases from lung adenocarcinoma may be utilized to provide insight into the EGFR mutation status and guide the clinicians for initiation of targeted therapy.

Download Full-text

Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis

Open Medicine ◽

10.1515/med-2016-0018 ◽

2016 ◽

Vol 11 (1) ◽

pp. 93-96 ◽

Cited By ~ 2

Author(s):

Jiang Rong ◽

Ma Chunhua ◽

Lv Yuan ◽

Mu Ning ◽

Li Jinduo ◽

...

Keyword(s):

Cerebrospinal Fluid ◽

Lung Adenocarcinoma ◽

Gene Mutation ◽

Direct Sequencing ◽

Gene Mutations ◽

Egfr Mutations ◽

Egfr Gene ◽

Sequencing Method ◽

Direct Sequencing Method ◽

Egfr Gene Mutation

AbstractObjectiveTo discuss the application of ARMS method to detect EGFR gene mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis.Methods5 cases of lung adenocarcinoma were identified with meningeal metastasis that were cleared EGFR gene mutation by gene sequencing method. From each patient 5ml cerebrospinal fluid was obtained by lumbar puncture. ARMS method was used to detect EGFR mutations in cerebrospinal fluid.Results5 samples of cerebrospinal fluid were successfully detected by ARMS method, 3 samples found that EGFR gene mutations, the mutations in line with direct sequencing method.ConclusionARMS method can be used to detect EGFR gene mutations of cerebrospinal fluid samples in lung adenocarcinoma with meningeal metastasis. But cerebrospinal fluid specimens from histological specimens, blood samples need to be confirmed by further comparative study whether there is advantage.

Download Full-text

Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000001043 ◽

2019 ◽

Vol 40 (8) ◽

pp. 842-849 ◽

Cited By ~ 4

Author(s):

Mengmeng Jiang ◽

Yiqian Zhang ◽

Junshen Xu ◽

Min Ji ◽

Yinglong Guo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Gene Mutation ◽

Small Cell ◽

Imaging Features ◽

Small Cell Lung ◽

Mutation Status ◽

Egfr Gene ◽

Pet Ct ◽

Egfr Gene Mutation

Download Full-text

LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation

10.1183/13993003.congress-2016.pa2880 ◽

2016 ◽

Author(s):

Marisol Arroyo Hernandez ◽

Alexander J. Alatorre ◽

Julio C. Garibay ◽

José F. Escobar ◽

Jerónimo Rodríguez

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Treatment Efficacy ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

A Case of EGFR Gene Mutation-positive Early Lung Adenocarcinoma That Recurred 12 Years Postoperatively with Meningeal Carcinomatosis Alone

Haigan ◽

10.2482/haigan.60.192 ◽

2020 ◽

Vol 60 (3) ◽

pp. 192-196

Author(s):

Keiichi Nakamura ◽

Yuka Fujita ◽

Chie Mori ◽

Hokuto Suzuki ◽

Hikaru Kuroda ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Meningeal Carcinomatosis ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

The value of Fn14, CD44v, and EGFR expression in lung adenocarcinoma patients with and without activating EGFR gene mutation.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e20514 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e20514-e20514

Author(s):

Maciej Bryl ◽

Katarzyna Bednarek-Rajewska ◽

Przemysław Zalewski ◽

Małgorzata Janicka-Jedyńska ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Prognostic Value ◽

Neoplastic Disease ◽

Study Group ◽

Secondary Resistance ◽

Egfr Gene ◽

Egfr Expression ◽

Nsclc Patients ◽

Egfr Gene Mutation

e20514 Background: Lung cancer is considered the most common cause of death in the world. The prognosis for patients is poor and depends on the clinical stage and the histological type of cancer. There is a need to identify and develop new therapeutic targets that could improve the prognosis of NSCLC patients and may be responsible for development of resistance to TKI therapy. Increased expression of Fn14 or CD44v and EGFR was observed in many tumors and also correlated with the overall survival of NSCLC patients Methods: We analyzed the clinical data and the immunohistochemical expression of Fn14, CD44v and EGFR in tumor tissues from 61 patients with NSCLC divided in two groups according to the presence of activating EGFR gene mutation. The aim of the study was to evaluate the correlation between the expression of the studied molecules and the neoplastic disease course of NSCLC patients. Results: Increased expression of Fn14 was observed in study group (B) compared to expression of this molecule in the control group (K). There were no differences in the intensity of the reaction with anti CD44v and EGFR antibodies in both groups. OS was significantly longer in the study group. Histological grade of tumor correlated with the intensity of CD44v expression in both groups. There was no correlation between the OS and Fn14 expression in any group. Negative correlation was noted between the expression of CD44v and the OS in the study group and between EGFR expression and the OS in both groups. Conclusions: Our observations suggest that the expression of CD44v and EGFR may be useful clinical markers of prognostic value in lung adenocarcinoma patients regardless of the presence of activating mutation in EGFR gene. Simultaneous assessment of Cd44v and EGFR expression may grant a greater prognostic value than the assessment of each receptor separately. Increased expression of Fn14 receptor in patients with EGFR gene mutation may become a new target in therapy allowing to eliminate the problem of secondary resistance to treatment with TKI’s

Download Full-text